Abbreviations, viii, 510t-511t
ACAM2000, 432, 433t, 435. See also Smallpox.
Access to vaccination, 121
Acetaminophen, 134
ACIP. See Advisory Committee on Immunization Practices.
ActHIB (Hib-T), 303-306, 304t-305t
in combination vaccine, 488t-491t
Active Bacterial Core surveillance (ABCs), 73
Acute disseminated encephalomyelitis (ADEM), 366
Acute otitis media (AOM), 441
Acyclovir, 168
Ad-hoc committees and task forces, 77
Adacel (Tdap), 42, 63t, 288t-290t, 296. See also Tdap vaccine.
Adaptive immune system, 23
Additives in vaccines, 226-227
Adenocarcinomas, HPV and, 332
Adenovirus, 269-273
clinical features, 269-270
epidemiology and transmission, 270
immunization program, 270
pathogen, 269
vaccines, 14t, 270-272, 271t
contraindications/precautions, 272
efficacy/immunogenicity, 272
recommendations, 272
safety, 272
storage, 114t
Adenylate cyclase toxin, 283
Adjuvants, 29-30, 224-226, 485. See also specific vaccines.
aluminum salts, 29-30, 225-226
AS04, 226
safety concerns, 224-226
Administration of vaccines, 126-134. See also Delivery of vaccines.
anxiety, pain, and fever, dealing with, 134
codes for, 136-137
emergencies following, 135-136
generals in, and remedies, 153, 156t-159t
genetics and, 47
IOM Consensus Report on, 77, 78t-79t
reporting system (VAERS), 74-75, 94
Advisory Commission on Childhood Vaccines (ACCV), 65
Administration of vaccines (continued)
intradermal, 127-134
intramuscular, 127, 131
intranasal, 127, 350
jet injectors, 134
multiple vaccines, simultaneous administration of, 127, 143, 160
oral, 127
preferred sites and needle length, 132t-133t
routes, 127-134, 131
schedules for. See Schedules.
subcutaneous, 127, 131
Adolescent immunization
coverage rates, 70, 71
hepatitis B vaccine, 258, 324
HIV-infected, 176-177
HPV vaccine, 107, 334, 343
mandates for, 107-109
schedules
catch-up, 262
routine, 258
standards for, 92-95
syncope and, 135
Td, 296
Tdap vaccine, 258, 287, 296
waning immunity and, 223
Adolescents, sexual activity among, 334
Adoptees, international, 189-190, 309, 314
Adult immunization
financing of, 86
mandates/legislation on, 106-109
older adults, 190, 360, 449
at pediatric office visit, 123t
schedules. See also specific vaccines.
by age group, 264-265
by medical condition, 266-267
standards for, 95-96, 96t
Adventitious agents, 245-246
Adverse events, 78t-79t. See also Vaccine Safety Net; specific vaccines.
emergencies following vaccine administration, 135-136
reporting, 93, 94, 102t
Reportable Events Table, 97, 98t-99t
reporting system (VAERS), 74-75, 94
Advisory Commission on Childhood Vaccines (ACCV), 65
Aspirin use, 202t, 359, 361
Reye syndrome and, 202t, 361
Asplenia, 172-173, 266-267
Association for Prevention Teaching and Research (APTR), 500
Association of State and Territorial Health Officials (ASTHO), 500
Asthma, 183, 229, 360
Attenuated vaccine, 14t
Attenuation of vaccines, 13-20
engineered, 19-20
heterologous host, 19
route of inoculation, 20
serial passage, 13-19
Autism, 231-237
genetic abnormalities and, 237
MMR vaccine and, 231-233, 376
thimerosal and, 184, 233-237, 237t, 238
Autoimmune disease, vaccines and, 163t, 228-230
Avian flu. See Bird flu.
Avian retrovirus particles, 245-246
B cells, 25, 25, 27, 28-29
B cell (humoral) deficiencies, 169
memory B-cells, 29
transformation into plasma cells, 29
Bacille Calmette-Guérin (BCG), 19
Bacillus anthracis, 275, 510t. See also Anthrax.
Bacteremia, 301, 441
Bacteria. See also specific bacteria.
lysis/opsonization of, 23
vaccines against, 37
BCG. See Bacille Calmette-Guérin.
Behavioral Risk Factor Surveillance System (BRFSS), 71, 501
Billing, 136-137, 138t-139t
coding for routine visit, 137, 138t-139t
costs of immunization, 77, 80t
Bone marrow transplantation. See Hematopoietic stem cell transplantation.
Books on vaccines, 502-503
Booster vaccination, 30, 31
Boostrix (Tdap), 52, 63t, 288t-290t, 294. See also Tdap vaccine.
Bordetella pertussis, 283, 285, 510t. See also Pertussis.
Brain damage, pertussis vaccine concerns, 239-240
Breast-feeding, 163t, 185. See also Pregnancy.
as contraindication
BRFSS (Behavioral Risk Factor Surveillance System), 71, 501
Brighton Collaboration, 76, 500
Buffers, 160, 485
Butte County, California (hepatitis A in), 44, 45
Cancer
chemotherapy for, 177-179
HPV and, 332, 333
polio vaccine, SV40 contamination and, 242-243
Carrier-induced epitopic suppression, 485-486
Catch-up immunization schedules
children, age 4 months-6 years, 260-261
children, age 7-18 years, 262
CBER, 55, 65
CD4, 27, 28, 34, 166, 176, 177
CD8, 34
CD46, 269
CDC. See Centers for Disease Control and Prevention.
Cell-mediated immunity defects, 169-172
Centers for Biologics Evaluation and Research (CBER), 55, 65
Centers for Disease Control and Prevention (CDC), 65, 143, 499
monitoring and, 72-73
vaccine policy and, 64
vaccine stockpiles, 88
web site, 66, 499
Centers for Medicare and Medicaid Services (CMS), 65, 499
Cerebrospinal fluid (CSF) leaks, 183, 202t
Cervarix (HPV2), 336t-338t. See also Human papillomavirus.
adjuvant in, 226
efficacy/immunogenicity, 340-341
safety, 342
Cervical cancer, 331, 332, 333, 343
Cervical intraepithelial neoplasia (CIA) grades, 332, 339, 343
Chickenpox. See Varicella.
Children. See also Adolescent immunization; Infants.
anxiety and pain, dealing with, 134
cocoon strategy, 122, 287
coding for routine visit, 137, 138t-139t
costs of immunization, 77, 80t
Children (continued)
coverage goals, 91-92
coverage rates, 69-71, 69, 70
HIV-exposed/infected, 168, 176
immune response in, 26
immunization schedules
catch-up, age 4 months-6 years, 260-261
catch-up, age 7-18 years, 262
combination vaccines, 257
financing for, 80-86, 81
grace period, 107, 144, 145
H influenzae, 303-306
hepatitis A, 51, 309
hepatitis B, 324
influenza, 349, 360
pneumonia, 448
polio, 401
routine, age 0-6 years, 256
routine, age 7-18 years, 258
school mandates, 107-109
tavel and, 194-195
varicella, 465-467
immunization standards, 92-95
natural protection in, 39
vaccine delivery, improving, 120t
Vaccines for Children (VFC) Program, 80-82, 93
Children’s Hospital of Philadelphia Vaccine Education Center, 500
Children’s Vaccine Program at PATH, 500
Chronic disease, impaired immunity and, 183
Chronic liver disease, 266-267, 314, 319, 325
Chronic lung disease, 183, 266-267
Cidofovir, 438
CISA (Clinical Immunization Safety Assessment) Network, 75, 500
Classification of vaccines, 14t-15t
Clinical Immunization Safety Assessment (CISA) Network, 75, 500
Clinical trials, 57-60, 57
numbers of subjects required, 57, 58-60, 59t
Clonal expansion, 24
Clostridium tetani, 283, 285, 510t. See also Tetanus.
Clotting-factor disorders, 314
CoCASA (Comprehensive Clinic Assessment Software Application), 125-126
Cochlear implants, 183, 202t
Cocooning strategy, 122, 287
Coding and billing, 136-137
CPT codes, 136
ICD-9-CM codes, 136-137
National Drug Codes (NDCs), 137
routine infant office visit (example), 137, 138t-139t
College students, vaccination of, 202t, 361, 394, 467
Combination vaccines, 485-497, 488t-495t, 511t
advantages of, 486-487
barriers to adoption of, 487
contraindications/precautions, 487-496
development, evaluation, and licensure of, 485-486
DTap-based, 488t-491t
efficacy/immunogenicity, 486, 487
minimum age for, 145
nomenclature, 486, 511t
noninferiority standard, 486
other, 492t-495t
overimmunization and, 496
preference for, 496
quality, effect on, 486-487
recommendations on, 62t, 496
safety, 487
schedule, 257, 488t-495t
Communicating about vaccines, 205-254. See also Concerns about vaccines, addressing.
antivaccinationism, 214-215, 216t-218t
public harm from, 215-219, 220t-221t
communicating risks and benefits, 205-211
language and meaning, 212t
meaning of safety, 205-206
sources of information, 209, 210
specific concerns and questions, 219-248
strategies for, 208-211
vaccine refusal, 211-214
Compensation. See Vaccine Injury Compensation Program.
Complement assays, 389
Complement deficiencies, 165-166, 172
Complement-mediated lysis, 23
Component vaccines, 20-21, 485. See also specific combination vaccines.
Comprehensive Clinic Assessment Software Application (CoCASA), 501
Comvax (HepB-Hib-OMP), 62t, 492t-495t
Concerns about vaccines, addressing, 205-254
antivaccinationism, 214-215, 216t
flawed thinking, 218t
protest organizations, 216t
public harm from, 215-219, 220t-221t
Concerns about vaccines, addressing (continued)
communicating risks and benefits, 205-211
communication strategies, 208-211
language and meaning, 212t
probabilistic and heuristic thinking, 206-207
sources of information, 209, 210
costs of public concern, 215-219, 220t-221t
perceptions/thoughts about vaccination, 206-207
specific concerns, 219-248
additives, safety of, 226-227
adjuvants, danger of, 224-226
AIDS, polio vaccine and, 243-244
allergies and autoimmune disease, 228-230
alternative schedules, 227-228
autism, MMR vaccine and, 231-233, 234
autism, thimerosol and, 233-237, 237t, 238
brain damage, pertussis vaccine and, 239-240
cancer, SV40 contamination and, 242-243
febrile seizures, 246-247
fetal tissue in vaccine manufacture, 230-231
Guillain-Barré syndrome, 240-241
Kawasaki disease, 244-245
mad cow disease, 242
multiple sclerosis, 241-242
multiple vaccines, immune overload and, 223-224, 225t
natural infection vs immunization, 222-223
necessity for vaccines, 219-222
polio vaccine, AIDS pandemic and, 243-244
polio vaccine, SV40 contamination in, 242-243
rotavirus vaccines and intussusception, 247-248
SIDS, 244
vaccine refusal, 211-214
public costs of, 215-219, 220t-221t
Condyloma acuminata, HPV and, 332
Confidentiality, protecting, 124-125
Confirmation bias, 207
Congenital rubella syndrome (CRS), 373, 375
Conjugate (protein-polysaccharide) vaccines, 32-34, 33, 35t
Contacts, immunization of, 167, 167t, 173, 324, 361, 457, 467
Contaminants, 245-246. See also specific vaccines.
Contraindications and precautions, 160-162.
See also specific vaccines.
distinguishing, 161-162
erroneous contraindications, 162, 163t-164t
screening for, 126, 128t-130t
Control, vs elimination/eradication, 48-49
Correctional facility staff/inmates, 203t, 309, 314, 319, 325, 361, 467
Correlates of protection, 38-42, 40t
Corynebacterium diphtheriae, 283, 285, 510t.
See also Diphtheria.
Costs, 77-87
cost-benefit analysis
influenza vaccination, 349
N meningitidis vaccination, 387
pneumococcal vaccination, 443
rabies, postexposure prophylaxis, 405
rotavirus vaccination, 419
routine childhood immunizations, 51
varicella vaccination, 462
zoster (shingles) vaccination, 223, 480
financing, 77-87
provider costs for vaccination services, 140t
of public concern about vaccines, 215-219, 220t-221t
of routine childhood vaccinations, 77, 80t, 140t
of vaccine development, 35
of vaccines (purchase price), 77, 80t, 137. See also specific vaccines.
Coverage, 68-72, 501-502
combination vaccines and, 486-487
goals, 91-92
monitoring, 67-72
rates, 69, 70
Cowpox, 19. See also Smallpox.
Cows, mad cow disease and, 242
CPT codes, 136, 138t-139t
Creutzfeldt-Jakob disease (vCJD), 242
Cross-protection, 31, 38
CSF leaks, 183, 202t
Culex mosquitoes, 366
Cytokines, 26
Cytotoxic T cells (Tc cells), 34-38, 36
implications for vaccination, 36-38
Cytotoxicity, 23
Cytotoxins, 34-36
Danish Cohort Study
MMR and autism, 233, 234
thimerosol and autism, 236-237, 238
Daptacel (DTaP), 288t-290t
Day care center staff, vaccination of, 203t, 315
Defense Medical Surveillance System (DMSS), 76
Delayed-type hypersensitivity, 160
Delivery of vaccines
improving, 118-126, 120t
expanding access, 121
Immunization Information Systems (IISs), 124-125
missed opportunities, 121
other strategies, 125-126
reminder, recall, and tracking systems, 118-121
standing orders, 122-123
monitoring, 68-72
Dendritic cells, 26
Department of Defense (DOD), 65, 76, 499
vaccination programs, 277, 429-432
Design defect claims, 100-101
Development. See Vaccine development and licensure.
Developmentally disabled institutions, 203t, 325
Diabetes, 183, 230
vaccination recommendations, 266-267, 319, 325
DiGeorge syndrome, 166, 169
Diphenhydramine, 136
Diphtheria, tetanus, and pertussis, 283-297, 510t.
See also individual entries for Diphtheria, Tetanus, Pertussis.
clinical features, 284-285
epidemiology and transmission, 285-286
immunization program, 286-287
pathogens, 283
vaccines, 287-291
efficacy/immunogenicity, 291
recommendations, 295-297
safety, 294-295
Diphtheria, 283-297. See also Pertussis; Tetanus.
clinical features, 284
epidemiology and transmission, 285
immunization program, 286
pathogen, 283
resurgence of, 286
toxoid, 152, 286
vaccines, 287-291, 288t-290t, 292t-293t. See also DT; DTaP vaccine; Tdap vaccine.
adult. See Tdap vaccine.
children/infants. See DTaP vaccine.
combination vaccines, 62t, 257, 488t-491t
contraindications/precautions, 294-295
efficacy/immunogenicity, 291
recommendations, 63t, 295-297
safety, 294-295
schedule, 295-297
storage, 114t, 116t
Diphtheria and Tetanus Toxoids Adsorbed USP (for Pediatric Use; DT), 292t-293t
Disease-modifying antirheumatic drugs (DMARDs), 178
Diseases, reporting, 72-73
DMARDs (disease-modifying antirheumatic drugs), 178
‘Do no harm’ dictum, 206
Dosing
administration errors, and remedies, 153, 156t-159t
partial or fractional, 145
Drug users, injecting, 202t, 314, 315, 325
Dryvax, 432, 435
DT (diphtheria, tetanus toxoids), 292t-293t
contraindications/precautions, 295
schedule, 296
DTaP vaccine, 288t-290t. See also Diphtheria, tetanus, and pertussis.
combination vaccines, 62t, 257, 488t-491t
contraindications/precautions, 161, 294-295
coverage, 69, 69
efficacy/immunogenicity, 291
GBS and, 294, 295
manufacturer, for series, 151
recommendations, 295-296
wound management, 298t-299t
safety, 294-295
schedule, 295-296
administration errors and remedies, 156t-157t
catch-up, children age 4 months-6 years, 260
children, age 0-6 years, 256, 257
minimum ages and intervals, 146t, 188
DTwP vaccine, 485
Education on immunizations, 125
Effectiveness
monitoring, 72-73
postmarketing studies of, 60
vs efficacy, 60
Efficacy
correlates of protection, 38-42, 40t
efficacy/immunogenicity. See specific vaccines.
Eggs, allergy to, 227, 358, 359
Elimination of disease, 48-49
Embryonic cells, use in vaccine production, 230-231
Emergencies, 134-136
anaphylaxis, 135-136
following vaccine administration, 135-136
power and weather, vaccine storage and handling during, 119t
preparation for, 134-135
Emergencies (continued)
standing orders for, 135
syncope, 135
Emerging Infections Program Network (CDC), 73
EMLA cream, 134
Encephalitis
Japanese, 365-370
measles and, 372
postvaccination (yellow fever vaccine), 474
smallpox and, 427
Encephalopathy, 239-240, 294, 295
acute, as vaccine contraindication, 161
concerns about, 239-240
End stage renal disease (ESRD), 266-267, 325
Engerix-B (HepB), 319-323, 320t-322t
in combination vaccines, 488t-495t
Engineered agent vaccines, 14t
Engineered antibodies, 22
Engineered attenuation, 19-20
Engineered subunits, 21
Entitlement program, VFC as, 82
Epidemiology and Prevention of Vaccine-Preventable Diseases. See “Pink Book”.
Epilepsy, 239
Epinephrine, 136
Epitopes, 23
epitope spreading, 30
epitopic suppression, carrier-induced, 485-486
Eradication of disease, 48-49
Erythema, 225-226, 294
Every Child by Two (ECBT), 500
See also specific vaccines.
Exemptions from school immunization requirements, 108
Extinction of disease, 48-49
Extrafollicular reaction, 24-26, 25

Families Fighting Flu, 500
FDA. See Food and Drug Administration (FDA).
Fear of vaccines, harm from, 215-219, 220t-221t
Febrile multiple organ-system failure, 474
Febrile seizures, 246-247, 375
Federal requirements regarding vaccination, 102t-103t
Fetal tissue in vaccine manufacture, 230-231
Fever, 134, 294
Filamentous hemagglutinin (FHA), 283
Fimbriae (FIM), 283
Financing of immunization, 77-87
adults, 86
children, 80-86, 81
cost of vaccines, 77, 80t
future, 86-87
public/private sector participation, 81
Flu. See Influenza.
Fluarix (IIV, influenza), 352t
Flulaval (IIV, influenza), 352t
Flumist (LAIV, live influenza), 352t
Fluvirin (IIV, influenza), 352t
Fluzone (IIV, influenza), 352t
Fluzone (IIV, influenza, intradermal), 350
Fluzone High Dose (IIV, influenza), 350, 352t
Fluzone Intradermal (IIV, influenza), 350, 353t
Folk numeracy, 207
Food and Drug Administration (FDA), 55, 65, 499
Food handlers, vaccination of, 202t, 315
Foresters, vaccination of, 202t
Formaldehyde, 226, 227
Fort Dix, New Jersey, 240
Freezers, 112-113
FUTURE studies, 335
GABHS (group A beta-hemolytic streptococcus), 460
Gardasil (HPV4), 336t-338t. See also Human papillomavirus.
efficacy/immunogenicity, 339-340
safety, 341-342
Gastroenteritis. See Rotavirus.
Gelatin, 227. See also specific vaccines.
Genes/genetics, 47
Genital warts, 334
Germinal center reaction, 29-47, 27
implications for vaccination, 29-47
Germline antibodies, 24-25
Global Alliance for Vaccines and Immunization (GAVI), 500
Gloves, 105
situations where not routinely needed, 105, 126
Good Clinical Practices (GCPs), 57
Good Laboratory Practices (GLPs), 55-57
Good Manufacturing Practices (GMPs), 55, 58, 87
Good Pharmacovigilence Practices (GPPs), 60
Governmental agencies and committees, 65, 499
Grace period, 107, 144, 145
GRADE approach, 67
Group A beta-hemolytic streptococcus (GABHS), 460
Guillain-Barré syndrome, 76, 240-241, 357
as contraindication/precaution
for diphtheria/tetanus/pertussis vaccines, 294, 295
for influenza vaccines, 359, 360
MCV4 and, 162, 241, 394

H1N1 influenza, 345-346, 348
Haemophilus influenzae type b (Hib), 301-306, 510t.
  See also Influenza.
clinical features, 301
epidemiology and transmission, 301-302
herd immunity and, 302
immunization program, 302
newborn/childhood protection against, 39
pathogen, 301
vaccines, 302, 304t-305t
  combination vaccines, 62t, 257, 488t-495t
contraindications/precautions, 303
correlates of protection, 302
efficacy/immunogenicity, 302-303
minimum ages and intervals, 146t, 188
optimizing immunity, 169-172
recommendations, 302, 303-306
safety, 303
schedule
  administration errors and remedies, 157t
catch-up, children age 4 months-6 years, 260
  children, age 0-6 years, 256, 257
storage, 114t
Handling, storage, and transport of vaccines, 111-118
Harm, public, from fear of vaccines, 215-219, 220t-221t
Harmless, definition of, 205-206
HAV. See Hepatitis A.
Havrix (HepA), 309-313, 310t-312t
  in combination vaccine, 492t-495t
HBIG. See Hepatitis B immune globulin (HBIG).
HBV. See Hepatitis B.
Health care personnel, 109, 191-194
  needlestick injuries/blood exposure, 104-106, 191-192
  vaccination recommendations, 191-194, 266-267
hepatitis B, 319, 325
influenza, 349
polio, 401
smallpox, 429
Health care reform law (2010), 80
Healthcare Effectiveness Data and Information Set (HEDIS),
72, 501

Healthy People 2020, 91-92, 124
coverage goals, 72, 91-92
Heart disease, 183, 266-267
HEDIS (Healthcare Effectiveness Data and Information Set),
72, 501
Helper T lymphocytes (Th cells), 27, 28-29
Hemagglutinin, 283, 345, 371
Hematopoietic stem cell transplantation (HSCT), 179-183
  vaccination recommendations, 180t-182t
Hemodialysis, 266-267
HepaGam B (hepatitis B immune globulin), 319
  interval for live vaccines and, 155t
Hepatitis A, 307-316, 510t
  in Butte County, California, 44, 45, 313
clinical features, 307
disease vs infection, 308
epidemiology and transmission, 307-308
herd immunity and, 44, 45, 309
immunization program, 308-309
pathogen, 307
risk factors, 308
vaccines, 309, 310t-312t
  combination vaccines, 492t-495t
contraindications/precautions, 313
coverage, 69, 69
efficacy/immunogenicity, 309-313
minimum ages and intervals, 146t
recommendations, 314-316
postexposure, 315-316
pre-exposure prophylaxis, 314
for travel, 195, 198t-200t
universal childhood immunization, 51, 309
safety, 313
schedule
  adults, by age, 264
  adults, by medical condition/indication, 267
  catch-up, children age 4 months-6 years, 261
  catch-up, children age 7-18 years, 262
  children, age 0-6 years, 256
  children, age 7-18 years, 258
Hepatitis B, 317-327, 510t
chronic carriers, 317-318
clinical features, 317-318
epidemiology and transmission, 318
HBsAg/HBsAb status and, 188, 192, 317, 319, 326-327
testing for, 192, 325-326
immunization program, 318-319
pathogen, 317
Hepatitis B (continued)
vaccines, 319, 320t-322t
administration errors and remedies, 157t
combination, 257, 488t-495t
contraindications/precautions, 323-324
coverage, 69, 69
efficacy/immunogenicity, 319-323
minimum ages and intervals, 146t
recommendations, 62t, 324-327
adult vaccination, 324-326
for health care personnel, 106, 191-192
for newborns, 185-188, 324
for nonoccupational exposures, 330t
for occupational exposures, 191-192, 328t-329t
postexposure prophylaxis, 326-327, 328t-330t
for preterm/low birth weight infants, 188, 324
for travel, 195
universal infant, child and adolescent immunization, 324
reportable events, 99t
safety, 323-324
MS and, 241-242, 323
SIDS and, 244
schedule
adults, by age, 264
adults, by medical condition/indication, 267
birth dose, 324
catch-up, children age 4 months-6 years, 260
catch-up, children age 7-18 years, 262
children, age 0-6 years, 256, 257
children, age 7-18 years, 258
standing orders for, 324, 325
Hepatitis B immune globulin (HBIG), 319
anaphylactic reaction to, 324
recommendations, 328t-330t
Hepatitis B surface antigen/antibody (HBsAg/HBsAb).
See Herd immunity, 42-47, 43, 309
threshold, 42-44, 43
Herpes zoster. See Zoster (herpes zoster; shingles).
Heterologous host, 19
Heterologous hyperimmune sera, 22
Heterologous infections, 224
Heterotypic responses, 31
Hib. See Haemophilus influenzae type b.
Hib-OMP. See PedvaxHIB.
Hib-T. See ActHIB.
Hiberix (HibT), 303-306, 304t-305t
HIV (human immunodeficiency virus) infection, 173-177
adults, 176-177
children/adolescents, 176-177
immunoprophylaxis and, 168
infants, 173, 176
postexposure prophylaxis, 106
universal precautions, 105
vaccination recommendations, 173-177, 266-267
contraindications/precautions, 166
hepatitis B, 325
HLAs (human leukocyte antigens), 28, 47
Homotypic responses, 31
Hooper, Edward, 243
Hospital workers, 109
Household contacts, immunization of, 167, 167t, 173, 324, 361, 457, 467
HPV. See Human papillomavirus (HPV).
HPV2. See Human papillomavirus (HPV), vaccines.
HPV4. See Human papillomavirus (HPV), vaccines.
HRV. See Rotavirus, vaccines.
Human embryo cell lines, 230-231
Human immunodeficiency virus. See HIV.
Human leukocyte antigens (HLAs), 28, 47
Human papillomavirus (HPV), 331-344, 510t
cancers and, 332, 333
clinical features, 332
epidemiology and transmission, 333
immunization program, 334-335
pathogen, 331
sexual activity and, 333
vaccines, 335, 336t-338t
contraindications/precautions, 152, 342
cross-protection from, 339
efficacy/immunogenicity, 335-341
HPV2 (Cervarix), 336t-338t
adjuvant in, 226
efficacy/immunogenicity, 340-341
HPV4 (Gardasil), 336t-338t
efficacy/immunogenicity, 339-340
immunization program, 334-335
schedule, 343
adults, by age, 264
adults, by medical condition/indication, 266
age 7-18 years, 258
catch-up, children age 7-18 years, 262
minimum ages and intervals, 146t-147t
manufacturer, for series, 151
Human papillomavirus (HPV) (continued)
recommendations, 343
safety, 341-342
school mandates, 107
storage, 115t
Human papillomavirus immune globulin (HRIG), 405-407, 414t-415t
Humoral immune deficiencies, 165, 169-172
Hundred-day cough, 284. See also Pertussis.
Hygiene hypothesis, 228-229
HyperHEP B S/D (hepatitis B immune globulin, human), 319
Hyperimmune globulins, 22
HyperRAB S/D (rabies immune globulin), 406
Hypersensitivity, delayed-type, 160
Hypersensitivity reactions, 225-226
HyperTET S/D (tetanus immune globulin), 291
Hyporesponsiveness, 26
ICD-9-CM codes, 136-137, 138t-139t
IGIM (intramuscular immune globulin), 127, 131
intervals for live vaccines and, 154t-155t
IGIV (immune globulin, intravenous), 154t-155t
IIV (inactivated influenza vaccine). See Influenza, vaccines, IIV.
Illegal drug users, vaccination of, 202t, 314, 315, 325
Immigrants, vaccination policies on, 189-190
Immune deficiency. See Impaired immunity.
Immune globulin, 22, 168. See also Antibodies; specific immune globulins.
administration procedure, 127, 131
intervals for vaccination with live vaccines, 152-153, 154t-155t
intramuscular (IGIM), 127, 131
intravenous (IGIV), 154t-155t
isotypes, 23
Immune memory, 29
Immune overload, 223-224, 225t
Immune response, 23-47
adaptive immune system, 23
anamnestic response, 29
antibodies, 23-24
  persistence of, 31-32
antigens, 13
cytotoxic T cells, 34-38, 36
extrafollicular reaction, 24-26, 25
genetics and, 47
germinal center reaction, 26-47, 27
homotypic vs heterotypic, 31
hygiene hypothesis, 228-229
Immune response (continued)
  innate immune system, 26
  stimulating, 29
  priming and boosting, 30, 31
Immune thrombocytopenic purpura, 377
Immunity
criteria/evidence for (in specific diseases), 382t-383t, 466t
impaired. See Impaired immunity.
proof of, 189
surrogates of protection, 38-42, 40t
wanning, 29, 190, 223, 287, 460
Immunization, 13-23
booster, 30, 31
correlates of protection, 38-42, 40t
definition of, 13
herd immunity, 42-47, 43
mandates and legislation regarding, 106-109
passive, 21-23
primary, 30, 31
reactions to. See Adverse events.
schedules. See Schedules for immunizations.
screening for, 126, 128t-130t
standards. See Standards, principles, and regulations.
Immunization Action Coalition (IAC), iv, 501
Immunization Information Systems (IISs), 121, 124-125
Immunization programs, 48-51. See also specific vaccines.
goals of, 48-49, 91-92
impact of, 49-51, 50t
Immunization Safety Review Committee (ISRC), 77
Immunocompromised states. See Impaired immunity.
Immune reactivity, 32-34. See also specific vaccines.
efficacy and, 38
Immunogenicity bridging studies, 58
Immunosuppression, 177-183. See also Impaired immunity.
caused by vaccines, 224
medication-induced, 177-178
Imogam Rabies-HT (rabies immune globulin), 406
Imovax Rabies (RAB-HDC), 63t, 408t-409t
Impact of vaccines, 49-51, 50t
Impaired immunity, 165-183
close contacts, immunization of, 167, 167t
genral considerations, 165-168
HIV infection, 173-177
medication-induced immunosuppression, 177-179
passive immunoprophylaxis, 168
specific states other than HIV infection, 169-173
transplantation, 177-178, 179-183, 180t-182t
vaccine recommendations, 266-267
Inactivated vaccines, 14t, 20-21
characteristics of, 16t-18t
intervals for vaccination, 144-145, 146t-150t
vs live vaccines, 16t-18t, 38
Infanrix (DTaP), 288t-290t, 291
in combination vaccine, 488t-491t
cost, 137
Infants, 185-188. See also Children.
cocooning strategy, 122, 287
H influenzae vaccination, 303
hepatitis B vaccination, 185-188, 324
HIV-exposed/infected, 173, 176
preterm and low birth weight, 188-189, 324
rotavirus vaccination, 176, 425-426
varicella vaccination, 465-467
Infectious Diseases Society of America (IDSA), 500
Influenza, 345-363, 510t
clinical features, 347
epidemics/pandemics, 345-346
2009 A(H1N1), 346, 348
Spanish flu (1918), 346
epidemiology and transmission, 347-349
immunization program, 349
mortality from, annual, 222, 348
pathogen, 345-346
strains, 350, 351
A(H1N1), 76, 345-346
A(H3N2), 345
A(H5N1), bird flu, 346, 347, 348-349
vaccine for, 350-351
B, 351
vaccines, 350-351, 352t-353t
annual production of, 350-351
contraindications/precautions, 358-359
cost-benefit analysis, 349
coverage, 71
efficacy/immunogenicity, 351-357
egg protein allergy and, 358, 359
Guillain-Barré syndrome and, 241, 357, 359, 360
IIV (inactivated), 351-356, 352t-353t
A (H5N1) vaccine, 350-351
contraindications/precautions, 358-359
differences from LAIV, 354t-355t
efficacy/immunogenicity, 351-356
high-dose, 350, 352t, 357
intradermal, 350, 353t, 358
production of, 350
safety, 357-358
Influenza, vaccines (continued)
LAIV (live-attenuated), 352t, 356-357
administration errors and remedies, 157t
contraindications/precautions, 173, 359-360
differences from IIV, 354t-355t
efficacy/immunogenicity, 356-357
intranasal administration, 127, 350
production of, 350
safety, 358
recommendations, 360-361
health care personnel, 192, 361
older adults, 190, 361
priority groups, 360-361
for travel, 195-196
safety, 357-360
schedule
adults, by age, 264
adults, by medical condition or indication, 266
children, age 0-6 years, 256
children, age 7-18 years, 258
shortages of, 88
swine flu, 76, 240, 346
Injection techniques and sites, 127, 131, 132t-133t
Injury. See National Childhood Vaccine Injury Act; Vaccine Injury Compensation Program.
Innate immunity, 26
stimulating, 29
Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, 501
Institute of Medicine (IOM), 77
Consensus Report, 77, 78t-79t
Immunization Safety Review Committee, 77
International adoptees, refugees, and immigrants, 189-190, 309, 314
International agencies, 499
Intervals for vaccinations, 143-145, 146t-150t
grace period, 107, 144, 145
inactivated vaccines, 144-145, 146t-150t
live vaccines, 143-145, 146t-150t
between live vaccines and antibody-containing blood products, 152-153, 154t-155t
minimum acceptable, 144-145, 146t-150t
simultaneous administration, 143, 160
Intramuscular (IM) administration of vaccines, 127, 131
Intramuscular (IM) immune globulin (IGIM), 127, 131
Intranasal administration of vaccines, 127, 350
Intravenous immune globulin (IGIV), 154t-155t
Intussusception, 247-248, 419
Invasive pneumococcal disease (IPD), 441, 442.

See also Pneumonia.

Inventory, 111

IOM. See Institute of Medicine.

IPOL (IPV), 400t. See also Polio, vaccines.

IPV. See Polio, vaccines.

Isotype switching, 29

ISRC. See Immunization Safety Review Committee.

Ixiaro (JE-VC), 62t, 368t

Japanese encephalitis, 365-370, 510t

clinical features, 365

epidemiology and transmission, 365-366

immunization program, 366-367

pathogen, 365

vaccines, 367, 368t

contraindications/precautions, 369

efficacy/immunogenicity, 367

JEV-MB, 367

JEV-VC, 62t, 367, 368t

recommendations, 367, 369

travel, 198t-200t, 369

safety, 367-369

schedule/storage, 368t

storage, 115t

Jaundice, 307, 471

Jenner, Edward, 19

Jet injectors, 134

JEV. See Japanese encephalitis.

Kawasaki disease, 244-245

Kidney failure, 266-267

Kinrix (DTaP-IPV), 488t-491t

Koplik’s spots, 372

Labeled indications, 61-64, 62t-63t

Laboratory workers, vaccination of, 107, 202t, 361, 401, 429, 439, 457

LAIV (live-attenuated influenza vaccine).

See Influenza, vaccines, LAIV (live-attenuated).

Langerhans cells, 26

Latex. See specific vaccines.

Leukemia, impaired immunity and, 179-183

Liability issues, 88, 101-102. See also National Childhood Vaccine Injury Act.

Licensure. See Vaccine development and licensure.

Live-attenuated influenza vaccine. See LAIV.

Live-attenuated vaccines, 14t

Live vaccines, 13-20

characteristics of, 16t-18t

intervals for receipt of antibody-containing products, 152-153, 154t-155t

intervals for vaccinations, 143-145, 146t-150t

live-attenuated, 13-20, 14t

pregnancy and, 161

vs inactivated vaccines, 16t-18t, 38

Liver disease, 266-267, 314, 319, 325

Local anesthetics, 134

Local reactions, 225-226, 294

Lockjaw, 284

Long-term care facilities, 107, 202t, 361

Low birth weight infants, 188-189, 324

Lung disease, 183, 266-267

Mad cow disease (MCD), 242

Major histocompatibility complex (MHC), 47

class I molecules (MHC-I), 34

class II molecules (MHC-II), 27, 28, 34

Mandates, 106-109

Manufacturers of vaccines, 87, 151, 503

interchangeability of vaccines, 151

Marketing claims, 61

MCV4, 387-388, 390t-392t. See also Neisseria meningitidis.

contraindications/precautions, 393-394

coverage, 70, 71

efficacy/immunogenicity, 389-393

Guillain-Barré syndrome and, 162, 241, 394

licensure of, 42

MCV4-CRM, 42, 388, 390t-392t, 393

MCV4-D, 388, 389-393, 390t-392t

recommendations, 62t, 173, 394

safety, 393-394

schedule

administration errors, and remedies, 157t-158t

adults, by age, 264

adults, by medical condition/indication, 267

catch-up, children age 4 months-6 years, 261

catch-up, children age 7-18 years, 262

children, age 0-6 years, 256

children, age 7-18 years, 258

minimum ages and intervals, 147t

shortages of, 88

storage, 115t

vs MPSV, 387-388, 394
Measles, Mumps, Rubella, 371-381, 510t
clinical features, 372-373
criteria/evidence of immunity, 380, 382t-383t
elimination in U.S., 49
epidemiology and transmission, 373-375
immunization program, 375-376
measles outbreak in Indiana, 219
pathogens, 371-372
resurgence of, 50-51, 50t, 222
vaccines (MMR), 375-376, 378t-379t
combination vaccine (MMRV), 375-376, 492t-495t.
See also MMR vaccine.
contraindications/precautions, 379
efficacy/immunogenicity, 376-377
impact of vaccine refusal (example), 219
interval for receipt of antibody-containing products,
153, 154t-155t
recommendations, 62t, 376, 380
health care personnel, 192-193
postexposure prophylaxis, 380
reportable events, 98t
safety, 377-379
- autism concerns, 231-233, 234, 376
- febrile seizures, 246-247, 375
- thimerosal concerns, 235
schedule
- adults, by age, 264
- adults, by medical condition/indication, 267
- catch-up, children age 4 months-6 years, 261
- catch-up, children age 7-18 years, 262
- children, age 0-6 years, 256, 257
- children, age 7-18 years, 258
- minimum ages and intervals, 22, 147t
storage, 115t-117t
vs MMRV, 375-376
Medicaid, 86
Medicare, 86
Medication-induced immunosuppression, 177-178
Membrane attack complex, 23
Memory B-cells, 29
Men who have sex with men, 202t, 266-267, 314, 324
Menactra (MCV4), 62t, 390t-392t
Meningitis, 385-386, 397. See also Neisseria meningitidis.
Meningitis Angels, 501
Meningococcal disease, vaccines. See Neisseria meningitidis.
Meningococcal polysaccharide conjugate vaccine, 4-valent.
See MPSV4.
Meningococcemia, 385

Meningococcus. See also Neisseria meningitidis.
Menomune-A/C/Y/W-135 (MPSV4), 390t-392t
Menveo (MCV4-CRM), 62t, 390t-392t
Mercury (thimerosal) in vaccines, 233-237, 237t, 238
MHC, MHC-I, MHC-II. See Major histocompatibility complex.
Military personnel, 202t
- adenovirus infections and, 269
- adenovirus vaccination, 272
- anthrax vaccination, 277, 279-282
- meningococcal vaccination, 394
- smallpox vaccination, 432
- varicella vaccination, 467
Minimum age for vaccination, 145
Minimum intervals for vaccinations, 144-145, 146t-150t
Missed opportunities, 121
MMR vaccine, 375-380, 387t-389t.
See also Measles, Mumps, Rubella.
MMR II, 375, 387t-389t
in combination vaccine (MMRV), 492t-495t
MMRV vaccine, 375-376, 492t-495t
contraindications/precautions, 487-492
febrile seizures and, 375
interval for receipt of antibody-containing products,
153, 154t-155t
schedule/recommendations, 257, 376
shortages of, 88
vs MMR, 375-376
Monitoring, 68-73
- adverse events. See Adverse events.
- vaccine delivery (coverage), 68-72
- vaccine effectiveness, 72-73
Morbidity and mortality, from vaccine-preventable diseases, 50t
Morbidity and Mortality Weekly Report, 66
Morticians, vaccination of, 202t
Mosquitoes
- Aedes aegypti, yellow fever and, 472
- Culex, Japanese encephalitis and, 366
MPSV4, 387, 390t-392t. See also Neisseria meningitidis.
contraindications/precautions, 393-394
efficacy/immunogenicity, 389-393
minimum ages and intervals, 147t
recommendations, 174t, 394
safety, 393-394
schedule
- adults, by age, 264
- adults, by medical condition/indication, 267
storage, 115t
vs MCV, 387-388, 394
Multidose vaccine series, dosing intervals, 151
Multidose vials, 112, 118
Multiple sclerosis, vaccines and, 241-242, 323
Multiple vaccines, simultaneous administration of, 127, 143, 160
immune overload, 223-224, 225t
number of antigens, 224, 225t
Mumps, 371-381. See also Measles, Mumps, Rubella.
clinical features, 372-373
criteria/evidence of immunity, 380, 382t-383t
epidemiology and transmission, 374
in health care settings, 192
immunization program, 375-376
pathogen, 371
resurgence of, 50-51, 50t, 222
vaccines (MMR), 375-380, 387t-389t
contraindications/precautions, 379
efficacy/immunogenicity, 376-377
recommendations, 380
safety, 377-379
*Mycobacterium bovis*, 19

Nabi-HB (hepatitis B immune globulin), 319
Nalp3 inflammasome, 30
National Center for Immunization and Respiratory Diseases (NCIRD), 64, 65, 72
National Childhood Encephalopathy Study (NCES), 239
National Childhood Vaccine Injury Act, 74, 77, 96-101
National Coation for Adult Immunization, 95
National Drug Codes (NDCs), 137
National Foundation for Infectious Diseases (NFID), 501
National Health Interview Survey (NHIS), 72, 502
National Immunization Survey (NIS), 69-71, 502
National Institute of Allergy and Infectious Diseases (NIAID), 499
National Institutes of Health (NIH), 57, 65
National Meningitis Association, 501
National Network for Immunization Information (NNi), 501
National Notifiable Disease Surveillance System (NNDSS), 72-73, 502
National Respiratory and Enteric Surveillance System (NREVSS), 73
National Rotavirus Strain Surveillance System (NRSSS), 73
National Vaccine Advisory Committee (NVAC), 65, 68, 499
immunization standards, 92-95
National Vaccine Injury Compensation Program (VICP), 65, 88, 97-101
National Vaccine Plan, 68
National Vaccine Program Office (NVPO), 65, 68, 499

Native Americans and Alaskans, 202t, 442
Natural infection, vs immunization, 222-223
Necessity for vaccines, 219-222
Needle length, 132t-133t
Needlestick injuries, 104-106, 191-192
Needlestick Safety and Prevention Act, 104
Negri bodies, 403
*Neisseria meningitidis*, 385-395, 510t
clinical features, 385-386
epidemiology and transmission, 386
immunization program, 386-388
pathogen, 385
vaccines, 388-389, 390t-392t. See also *MCV4; MPSV4*.
contraindications/precautions, 393-394
cost-benefit analysis, 387
efficacy/immunogenicity, 389-393
herd effects, 44-47
MCV4, 387-388
MCV4-CRM, 388, 390t-392t
MCV4-D, 388, 389-393, 390t-392t
MPSV4, 387, 389-393, 390t-392t
optimizing immunity, 174t-175t
recommendations, 173, 174t, 394
travel, 196, 198t-200t
safety, 393-394
Neomycin, 227
Nephrotic syndrome, 183
Neuraminidase, 345, 371
Neutralization of viruses/toxins, 23
New Vaccine Surveillance Network (NVSN), 73
Newborns, 185-188. See also *Infants*.
Nomenclature, 510t-511t
Nonattenuatec vaccines, 14t
Noninferiority, 58, 486

Occupational Safety and Health Administration (OSHA), 104-106
Office visit
coding and billing example, 137, 138t-139t
communicating about vaccines in, 208
vaccination during, 122, 123t
Opsonization, 23
OPV. See *Polio, vaccines*.
Oral administration of vaccines, 127
OSHA. See *Occupational Safety and Health Administration*.
Otitis media, 460
Package insert (PI), 61, 168
Pain, dealing with, 134
Pan American Health Organization (PAHO), 499
Pap test, 332, 343
Parents of Kids With Infectious Diseases (PKID), 501
PARSIFAL study, 230
Partial doses, 145
Passive immunization, 21-23
Passive immunoprophylaxis, 168
Pasteur, Louis, 19, 20
Pathogen-specific molecular patterns, 26
Patient Protection and Affordable Care Act, 80
PATRICIA study, 340
Patternicity, 207
PCV7. See Pneumococcal vaccines, PCV7.
Pediariix (DTaP-HepB-IPV), 62t, 488t-491t
Pediatric immunization. See Children; Infants.
Pediatric Infectious Diseases Society (PIDS), 500
PedvaxHIB (Hib-OMP), 304t-305t, 306
in combination vaccine, 492t-495t
Pentacel (DTaP-IPV/Hib-T), 488t-491t
Permissive statements, 67
Personal belief exemptions, 108
Pertactin (PRN), 283
Pertussis, 283-297. See also Diphtheria; Tetanus.
catarrhal, paroxysmal, and convalescent stages, 284
clinical features, 284-285
epidemiology and transmission, 285-286
in health care settings, 193
immunity from natural infection, 222-223
immunization program, 287
incidence, 286
pathogen, 283
resurgence of, 50, 50t, 222, 286, 287
toxin (PT), 283
vaccines, 287-291, 288t-290t
acellular, 291
adult. See Tdap vaccine.
children/infants. See DTaP vaccine.
combination vaccines, 62t, 257, 488t-491t
contraindications/precautions, 294-295
efficacy/immunogenicity, 291
recommendations, 63t, 295-297
safety, 294-295
safety fears, brain damage, 239-240
schedule, 295-297
waning immunity and, 223, 287
Phagocyte disorders, 165, 172
Phase 1, 2, 3, and 4 trials, 57, 58-60
Philosophical exemptions, 108
Physical examination, no requirement for, 160
“Pink Book” (Epidemiology and Prevention of Vaccine-Preventable Diseases), 66
Plasma cells, 24, 25, 25
Pneumococcal vaccines, 444, 446t-447t
contraindications/precautions, 152, 448
cost-benefit analysis, 443
efficacy/immunogenicity, 444-445
immunization program, 442-444
minimum ages and intervals, 147t
optimizing immunity with, 170t-171t
PCV7, 443-444
contraindications/precautions, 448
efficacy/immunogenicity, 444-445
herd immunity and, 44-47, 46
recommendations, 448
replacement by PCV13, 47, 444
schedule, children, 256, 261
shortages of, 88
PCV13, 51, 444, 446t-447t
efficacy/immunogenicity, 445
recommendations, 62t, 173, 444, 448
replacement of PCV7 with, 47
safety, 448
schedule, 448
PPSV23, 444, 446t-447t
administration errors and remedies, 158t
efficacy/immunogenicity, 445
precautions, 152
recommendations, 170t, 173, 449
older adults, 190, 449
safety, 448
schedule
adults, by age, 264
adults, by medical condition/indication, 267
children, age 7-18 years, 258
recommendations, 448-449
safety, 448
storage, 116t
Pneumonia, 441-450. See also Pneumococcal vaccines.
clinical features, 441-442
epidemiology and transmission, 442
immunization program, 442-444
optimizing immunity, 170t-171t
Pneumonia (continued)
pathogen, 441
secondary to flu, 347
vaccines, 444, 446t-447t
Pneumovax 23 (PPSV23), 446t-447t. See also Pneumococcal vaccines.
recommendations, 449
safety, 445, 448
schedule, 258, 264, 267
Policy. See Vaccine policy.
Polio, 397-402, 510t
clinical features, 397
eliminated from U.S., 49
epidemiology and transmission, 397-398
global eradication initiative, 398-399
immunization program, 398-399
last indigenous case in U.S., 398
pathogen, 397
vaccines, 399, 400t
AIDS pandemic, concerns about, 243-244
cancer and, concerns about, 242-243
combination vaccines, 257, 485, 488t-495t
inactivated (IPV), 400t
contraindications/precautions, 401
efficacy/immunogenicity, 399
minimum ages and intervals for, 147t
recommendations, 62t, 401-402
safety, 399
schedule, 400t
catch-up, children 7-18 years, 262
children, age 4 months-6 years, 261
children, age 0-6 years, 256, 257
children, age 7-18 years, 258
oral (OPV), 62t, 399
reportable events, 98t
recommendations, 62t, 399, 401-402
tavel in endemic areas, 196, 198t-200t
safety, 401
storage, 115t
SV40 contamination and, 242-243
Polio. See Polio.
Polyclonal immune globulins, 22
Polysaccharide antigens, 25-26, 25
Polysaccharide vaccines, 21, 25-26
hyporesponsiveness and, 26
original polysaccharide sin, 26
protein-polysaccharide vaccines, 32-34, 33
advantages of, 35t
Porcine circovirus, 246
Postherpetic neuralgia (PHN), 223, 477, 478
Postvaccination encephalitis, 474
Power supply/outages, 113-118, 119t
PPSV23. See Pneumococcal vaccines, PPSV23.
Precautions. See Contraindications and precautions.
Pregnancy, 183-185
FDA Pregnancy Categories, 184-185
live vaccines and, 161, 184-185
natural immunization of fetus during, 21-22
rubella in, effects on fetus, 373
vaccination during, 183-185, 186t-187t
contraindications/precautions, 184, 185
counseling for, 184
hepatitis B, 326
influenza, 184, 359, 361
JEV, 369
live vaccines, 184, 186t-187t
routine schedule, 266-267
Tdap and Td, 184, 297
varicella, 467
VariZIG, 185, 467-468
yellow fever, 161, 476
PREP Act, 101-104
Prevention Drug User Fee Act (PDUFA), 60
Preservative-free vaccines. See also specific vaccines.
Preservatives. See also specific vaccines.
Preventive and low birth weight infants, 188-189, 324
Prevention of infection, 22, 23-24, 32, 37
Prevnar. See Pneumococcal vaccines: PCV7, PCV13
Primary immunization, 30, 31
Probabilistic thinking, 206
Production problems, 88
Professional associations, 499-500
Proof of immunity, 106-107
ProQuad (MMRV), 492t-495t
Protein-polysaccharide vaccines, 32-34, 33, 302
advantages of, 35t
Protest organizations (antivaccination), 214-215, 217t
Pseudomembranes, 283
Public health, 48-51. See also Concerns about vaccines, addressing.
immunization programs, 48-49
impact of vaccines, 49-51, 50t
risks of refusal of vaccination, 213, 215-219, 220t-221t
Public health emergency, 101-104
Public Readiness and Emergency Preparedness Act, 101-104, 438
Public safety workers, vaccination of, 202t, 325
Purified subunits, 14t, 20-21
*Purpura fulminans*, 385. See also *Neisseria meningitidis*.

Questions about vaccines. See *Concerns about vaccines*.

RAB-HDC. See *Imovax Rabies*.
RAB-PCEC. See *RabAvert*.
Rabies, 403-407, 510t
   clinical features, 403-404
   epidemiology and transmission, 404
   immunization program, 405
   incubation period, 403, 405
   pathogen, 403
   vaccines, 406, 408t-409t. See also *Rabies immune globulin, human (HRIG)*.
   administration errors and remedies, 158t
   for animal handlers, 107
   contraindications/precautions, 406-407
   efficacy/immunogenicity, 406
   postexposure prophylaxis, 405, 412t-413t
   regimens for, 414t-415t
   pre-exposure prophylaxis, 153-160, 410t-411t
   recommendations, 63t, 405, 407, 410t-415t
   safety, 406-407
   storage, 116t
   for wildlife, 404
Rabies immune globulin, human (HRIG), 405, 406, 414t-415t
   contraindications/precautions, 406-407
   efficacy/immunogenicity, 406
   regimens, 414t-415t
   safety, 406
Ramsay Hunt syndrome, 478
Reactions. See also *Adverse events*.
   anaphylaxis, 98t-99t, 135-136
   local reactions, 225-226, 294
Reassortment, 345, 350
Recall and tracking systems, 118-121
Recombinant DNA technology, 21
Recombinant subunit vaccines, 14t, 21
Recombivax HB (HepB), 320t-322t, 323
   in combination vaccine, 492t-495t
Recommendations, 143-164. See also *specific vaccines*.
   ACIP, ix, 66-67
   administration errors, 153, 156t-159t
   catch-up immunization, 66-67
   contraindications and precautions, 160-162
   intervals for receipt of antibody-containing products, 152-153, 154t-155t
   minimum age and intervals, 143-145, 146t-150t
   permissive statements, 67
   risk-based immunization, 67
   routine immunization, 66
   rules for vaccination, 143-160
   vaccination of persons who have had the disease, 152
   vaccine handling, storage, and transport, 111-118, 114t-117t
   vaccine manufacturers, 151
   vs package insert, 61-64, 62t-63t, 168
Reconstitution of vaccine, 112, 113, 126
Recurrent respiratory papillomatosis, 332
“Red Book” (*Report of the Committee on Infectious Diseases*), 67
Reference resources, 499-503
Refrigerators and freezers, 112-113
Refugees, international, 189-190
Refusal of vaccination, 211-214
   forms for, 213
   impact of, examples, 219, 220t-221t
   public cost of, 215-219
Registries, 124-125
Regulations. See *Standards, principles, and regulations*.
Religious exemptions, 108
Reminder, recall, and tracking systems, 118-121
*Report of the Committee on Infectious Diseases*.
   See “Red Book”.
Reportable Events Table, 97, 98t-99t
Reporting, 93, 94, 102t
   to VAERS, 74-75, 94, 101, 102t
Respiratory syncytial virus, monoclonal antibody (RSVmAB), 22, 23
Responsible person, 111, 112t
REST (Rotavirus Efficacy and Safety Trial), 420
Reverse genetics, 350
Reverse vaccinology, 21
Reye syndrome, 202t, 361, 460
RhoGAM (IM), interval for live vaccines and, 155t
Risk-based immunization recommendations, 67
Risks, perceived, 206-207
Risks and benefits of vaccines
   communicating about, 205-211
   public health risk of vaccine refusals, 213, 219, 220t-221t
   thought processes about, 206-207
Rose spots, 451
Rotarix (rotavirus, RV1), 63t, 420, 422t-424t
  efficacy/immunogenicity, 420-421
  safety, 421
RotaShield (RRV-TV), 418-419
RotaTeq (rotavirus, RV5), 63t, 419, 420, 422t-424t.
  See also Rotavirus.
  efficacy/immunogenicity, 420
  safety, 421
Rotavirus, 417-426, 510t
  clinical features, 417
  epidemiology and transmission, 417-418
  immunization program, 418-419
  monitoring/surveillance, 73
  pathogen, 417
  Rotavirus Efficacy and Safety Trial (REST), 420
  vaccines, 420, 422t-424t
    contraindications/precautions, 425
    cost-benefit analysis, 419
    efficacy/immunogenicity, 420-421
    manufacturer, for series, 151
    minimum ages and intervals, 148t
    recommendations, 63t, 176, 425-426
      for preterm infants, 188-189
    RRV-TV, 418-419
    RV-1, 63t, 420, 422t-424t
    RV-5, 63t, 419, 420, 422t-424t
    safety, 421-425
      intussusception concerns, 247-248, 419
      Kawasaki disease concerns, 245
      porcine circovirus contamination, 246
    schedule
      all infants, 425-426
      catch-up, children, 4 months-6 years, 260
      children, age 0-6 years, 256
  Routes of administration, 20, 127-134, 131
  RRV-TV (rhesus rotavirus vaccine; RotaShield), 418-419
  RSV mAS (Synagis), 22
  RSV. See Respiratory syncytial virus (RSV).
Rubella, 371-381. See also Measles, Mumps, Rubella.
  clinical features, 373
  congenital rubella syndrome (CRS), 373, 375
  criteria/evidence of immunity, 380, 382t-383t
  eliminated from U.S., 49, 192-193
  epidemiology and transmission, 375
  immunization program, 375-376
  pathogen, 371-372
  in pregnant women, 373
  vaccines (MMR), 375-380, 387t-389t
Rubella (continued)
  contraindications/precautions, 379
  efficacy/immunogenicity, 377
  recommendations, 192-193, 380
  safety, 377-379
Rubeola. See Measles.
Rules for vaccination, 143-160. See also Recommendations.

Sabin, Albert, 13
Sabin Vaccine Institute (SVI), 501
Safety, meaning of, 205-206
Safety of vaccines. See also Adverse events; specific vaccines.
  communicating about, 205-254
  definitions of, 205-206
  organizations on, 500-501
  perceptions/thoughts about vaccination, 206-207
  specific concerns, 219-248
  Vaccine Safety Net, 73-77
Salicylate use. See Aspirin use.
Salk, Jonas, 20
Salmonella enterica, 451
Salmonella typhi, 451. See also Typhoid fever.
Schedules for immunizations, 255. See also specific vaccines.
  adults, by age group, 264-265
  adults, by medical condition, 266-267
  catch-up schedule, children age 4 months-6 years, 260-261
  catch-up schedule, children age 7-18 years, 262
  children, age 0-6 years, 256, 257
  children, age 7-18 years, 258
  modified/alternative, 227-228
SCHIP (State Children’s Health Insurance Program), 82
Schools
  school mandates, 107-109
  school surveys, 72
  as sites for vaccination, 121-122
Screening, 126, 128t-130t
Section 317 Funds, 81, 82
Serial passage, 13-19
Seroconversion, testing for, 153-160
Serology, 153-160
Serotype replacement, 46-47
Sewage workers, 203t
Shingles. See Zoster (herpes zoster; shingles).
Shortages of vaccines, 87-88
Shots by STFM, 501
Sickle cell disease, 172, 183, 302, 361
Side effects. See Adverse events.
SIDS (sudden infant death syndrome), 244
Simian immunodeficiency virus (SIV), 243
Simian virus 40 (SV40), 242-243
Smallpox, 427-440, 511t
bioterrorism potential of, 428-429
clinical features, 427-428
diagnosis of, 428, 430t-431t
epidemiology and transmission, 428-429
eradication of, 48-49, 428
immunization program, 429-432
last remaining stocks of, 48-49
pathogen, 427
Smallpox Health Care Teams, 438
Smallpox Response Teams, 429
vaccines, 432-435, 433t
ACAM2000, 432, 433t, 435
administration, 432-434
contraindications/precautions, 185, 436-437
Dryvax, 432, 435
efficacy/immunogenicity, 435
intradermal administration, 127-134
postevent vaccination, 429
postvaccination care, 434-435
pre-event vaccination, 429, 439
recommendations, 438-439
reconstitution, 432
ring vaccination (surveillance and containment), 429
safety, 435-438
storage, 117t
vaccinia immune globulin (VIG), 428
vs chickenpox, 428, 430t-431t
Smoking, 183
Society of Teachers of Family Medicine (STFM), 501
Spanish flu, 346
Special circumstances, 165-204
adults over 65 years of age, 190
health care personnel, 191-194
impaired immunity, 165-183
general considerations, 165-168
hematopoietic stem cell transplantation and leukemia,
179-183, 180t-182t
HIV infection, 173-177
medication-induced immunosuppression, 177-179
specific states other than HIV infection, 169-173
international adoptees, refugees, and immigrants, 189-190
newborns, 185-188
other special circumstances, 196, 202t-203t
predisposing conditions (other than immune deficiency), 183
Special circumstances (continued)
pregnancy and breast-feeding, 183-184
preterm and low birth weight infants, 188-189
travel, 194-196, 198t-200t
Spelunkers, 203t
Split doses, 145
Standards, principles, and regulations, 91-110
Bloodborne Pathogens Standard, 104-106, 191-192
federal requirements, 102t-103t
Healthy People 2020, 91-92
immunization practices, standards, 92-96
adult, 95-96, 96t
child and adolescent, 92-95
mandates, 106-109
National Childhood Vaccine Injury Act, 96-101
Occupational Safety and Health Administration, 104-106
Public Readiness and Emergency Preparedness Act, 101-104
for vaccine development (CBER), 55
Standing orders, 122-123
for emergencies, 135
for hepatitis B vaccination, 324, 325
State and local funds for vaccination, 81, 82-86
State Children’s Health Insurance Program (SCHIP), 82
State health department web sites, 503
State mandates, 106-109
Steroids, impaired immunity and, 178
Stockpiles of vaccines, 88
Storage of vaccines, 112-118, 114t-117t. See also specific vaccines.
during emergencies, 119t
Streptococcus pneumoniae, 441-450, 511t
clinical features, 441-442
epidemiology and transmission, 442
immunization program, 442-444
newborn protection against, 22
pathogen, 441
vaccines for, 444-449, 446t-447t. See also Pneumococcal vaccines.
recommendations, 448-449
safety, 448
Students. See College students.
Subcutaneous (SC) administration of vaccines, 127, 131
Subunits
engineered, 21
purified, 20-21
recombinant, 14t, 21
Sudden infant death syndrome (SIDS), 244
Supply of vaccines, 87-88
Surrogates of protection, 38-42, 40t
Surveillance, 72-76
SV40 contamination of polio vaccine, 242-243
Swine flu vaccine, 76, 240, 346
Synagis (RSV immune globulin, monoclonal, IM), 22
Syncope, 135
T-cell dependent response, 34, 35t
T-cell independent antigens and responses, 25-26, 34, 35t
T-cell receptor (TCR), 28, 34
T cells, 28, 166
   cytotoxic (Tc cells), 34-38, 36
   helper (Th-cells), 27, 28-29
      memory Th-cells, 29
   T-cell deficiencies, 169-172
T lymphocytes. See T cells.
Task Force on Safer Childhood Vaccines, 77
Tc cells (cytotoxic T cells), 34-38, 36
Td (tetanus, diphtheria) vaccine, 292t-293t
   contraindications/precautions, 295
   minimum ages and intervals for, 148t
   recommendations
      travel, 196
      wound management, 298t-299t
   schedule
      adults, by age, 264
      adults, by medical condition/indication, 266
      catch-up, children age 7-18 years, 262
Tdap vaccine, 288t-290t. See also Diphtheria, tetanus, and pertussis; DTaP.
   adolescent immunization, 287
   contraindications/precautions, 295
   coverage, 70, 71
   efficacy/immunogenicity, 291
   licensure, 42
   minimum ages and intervals, 148t
   recommendations, 63t, 296-297
      health care personnel, 193
      wound management, 298t-299t
   safety, 294, 295
   schedule, 296-297
      administration errors and remedies, 158t
      adults, by age, 264
      adults, by medical condition/indication, 266
      catch-up, children, age 7-18 years, 262
      children, age 7-18 years, 258
Tenivac, 292t-293t
Terminology, viii-ix, 510t-511t

Terrorism, 48-49, 428-429
Tetanospasmin, 283
Tetanus, 283-297. See also Diphtheria; Pertussis.
   clinical features, 284
   epidemiology and transmission, 285
   immunization program, 286-287
   lockjaw, 284
   neonatal, 284, 285
   pathogen, 283
   spores, 283, 285
   toxin, 283
   toxoid (TT), 298t-299t
   vaccination for travel, 196
   vaccines, 287-291, 288t-290t, 292t-293t.
      See also DT; Tetanus toxoid (TT).
      adult. See Tdap vaccine.
      children/infants. See DTaP vaccine.
      combination vaccines, 62t, 237, 488t-491t
      contraindications/precautions, 294-295
      efficacy/immunogenicity, 291
      minimum ages and intervals, 148t
      recommendations, 63t, 295-297
      wound management, 298t-299t
      safety, 294-295
      schedule, 295-297
      storage, 116t
   Tetanus and Diphtheria Toxoids Adsorbed (Td), 292t-293t
   Tetanus immune globulin (TIG), 284, 291, 298t-299t
   for at-risk HIV-infected children, 168
   Tetanus Toxoid Adsorbed (TT), 292t-293t
   Tetanus toxoid (TT), 286
      contraindications/precautions, 152, 295
      recommendations, 298t-299t
Texas Children’s Hospital Center for Vaccine Awareness and Research, 501
Th-cells (helper T lymphocytes), 27, 28-29
   memory Th-cells, 29
Th1-cells, 28
Th2-cells, 27, 28
Thimerosal, 87, 233-237, 237t, 361. See also specific vaccines.
   autism and, 184, 233-237, 238
Thrombocytopenia/thrombocytopenic purpura, 377
   TIG. See Tetanus immune globulin.
Timeliness, 68
Toll-like receptors (TLRs), 26
Topical anesthetics, 134
Toxins, 23, 34-36, 283
concerns about, 226
neutralization of, 23
Toxoid vaccines, 14t, 20
Tracheal cytotoxin, 283
Tracking systems, 118-121
Transplantation
hematopoietic stem cell (HSCT), 179-183
solid organ, 177-179
Transportation of vaccines, 111-118
Travel
and potential for disease outbreaks, 219, 222
vaccination for, 194-196, 198t-200t
hepatitis A, 309, 314
hepatitis B, 325
influenza, 361
MCV4, 394
polio, 401
typhoid, 457
Trials, clinical, 57-60, 57
Tsar/Tsarina for Vaccines, 111, 112t, 125
TT. See Tetanus toxoid (TT).
TViPSV. See Typhim Vi.
Twinrix (HepA-HepB), 492t-495t
Ty21a. See Vivotif.
Typhim Vi (TViPSV, pure polysaccharide vaccine), 454t-455t
efficacy/immunogenicity, 453
safety, 456
Typhoid fever, 451-458, 511t
clinical features, 451-452
epidemiology and transmission, 452
immunization program, 452-453
multidrug-resistant infection, 452-453
pathogen, 451
vaccines, 453, 454t-455t
contraindications/precautions, 456
efficacy/immunogenicity, 453-456
recommendations, 453, 457
safety, 456
storage, 116t

Universal precautions, 105
US Agency for International Development (USAID), 65, 499
Utility of vaccines, thinking about, 206-207

Vaccinate Your Baby, 501
Vaccination. See also Immunization; Vaccinology.
– basic concepts, 13-53

Vaccination (continued)
defined, 13
goals of, 48-49, 91-92
public health impact, 49-51, 50t
Vaccination programs, 49-51, 50t
Vaccination refusal, 211-214
Vaccine(s). See also Immunization; specific vaccines.
classification, 14t-15t
communicating about, 205-254
concerns about, addressing, 205-254
continuing necessity of, 219-222
correlates of protection, 38-42, 40t
costs/cost-benefit analyses. See Costs.
delivery. See Delivery of vaccines.
development. See Vaccine development and licensure.
equivalence of different manufacturers, 151
funding for. See Financing.
impact of, 49-51, 50t, 205
inactivated, 20-21
licensure. See Vaccine development and licensure.
live, 13-20
nomenclature and abbreviations, viii
number of/timeline, 51, 52
recommendations regarding. See Recommendations.
schedules for. See Schedules for immunizations.
supply/shortages, 87-88
Vaccine Adverse Event Reporting System (VAERS), 65, 74-75, 94, 101
federal requirements, 101, 102t
Vaccine and Treatment Evaluation Unit (VTEU), 65
Vaccine development and licensure, 55-64, 56
agencies involved with, 65
Biologics License Application (BLA), 60
clinical trials, 57-60, 57
package insert (PI), 61-64, 62t-63t
VRBPAC, 60-61
Vaccine immunology, 23-47. See also Immune response.
Vaccine Information Statements (VISs), 93, 101, 102t
Vaccine infrastructure in the U.S., 55-90
financing, 77-87
governmental agencies, 65
monitoring delivery, 68-72
monitoring effectiveness, 72-73
policy and recommendations, 64-68, 65
supply issues, 87-88
vaccine development and licensure, 55-64, 56
Vaccine Safety Net, 73-77
Vaccine Injury Compensation Program (VICP), 88, 97-101
covered vaccines, 100, 103t
Reportable Events Table, 97, 98t-99t
Vaccine Injury Table (VIT), 97-100
Vaccine policy and recommendations, 64-68.
   See also Recommendations.
agencies involved with, 64, 65
Vaccine practice, 111-142
   administration, 126-134
coding, billing, and costs, 136-137
delivery, improving, 118-126, 120t
emergencies, 134-136
handling, storage, and transport, 111-118, 114t-117t
screening, 126, 128t-130t
Vaccine Tsar/Tsarine, 111, 112t, 125
Vaccine-preventable diseases, 49-51
   monitoring, 72-73
   morbidity and mortality from, 50t
timeline for, 52
Vaccine protest organizations, 216t
Vaccine recommendations. See Recommendations.
Vaccine registries, 124-125
Vaccine Safety DataLink (VSD), 75, 230, 294
Vaccine Safety Net, 73-77
Vaccine Tsar/Tsarine, 111, 112t, 125
Vaccines and Related Biological Products Advisory Committee
   (VRBPAC), 60-61, 65
Vaccines for Children (VFC) Program, 64, 80-82, 93
   ACIP and, 68
   actions required under, 83t
   common questions about, 84t-85t
Vaccines.gov, 501
Vaccinia immune globulin (VIG), 438
Vaccinia virus, 19, 48, 427. See also Smallpox.
Vaccinology, 13-53. See also Immunization.
   basic vaccine immunology, 23-47
correlates of protection, 38-42, 40t
genetics of vaccine responses/adverse events, 47
herd immunity, 42-47, 43
   immunization, 13-23
   public health and vaccines, 48-51
Vaccinomics, 47
VAERS. See Vaccine Adverse Event Reporting System.
Vaginal intraepithelial neoplasia (VaIN), 332
Vaqta (HepA), 310t-312t, 313
Varicella, 459-469, 511t
   breakthrough/vaccine-modified, 459-460
   chickenpox and, 37, 152
Varicella (continued)
   childhood infection with, 37, 459
   clinical features, 459-460
   congenital, hemorrhagic, progressive, 460
criteria/evidence of immunity, 465, 466t
diagnosis, vs smallpox, 428, 430t-431t
epidemiology and transmission, 460-461
herpes zoster (shingles) and, 459. See also Zoster.
immunization program, 461-462
latent infection, 22, 37, 459
reactivation of, 37, 459, 460, 477
nosocomial transmission, 193
passive immunoprophylaxis (VariZIG), 168, 467-468
pathogen (varicella-zoster virus, VZV), 459
vaccines, 462, 463t
administration errors and remedies, 159t
contraindications/precautions, 166, 465
cost-benefit of vaccination, 462
coverage, 69, 69, 70, 71
efficacy/immunogenicity, 462-464
interval for receipt of antibody-containing products, 153, 155t
minimum ages and intervals, 22, 148t
   recommendations, 51, 62t, 152, 168, 465-468
   health care personnel, 193-194
   safety, 464-465
   schedule
   adults, by age, 264
   adults, by medical condition/indication, 266
   catch-up, children age 4 months-6 years, 261
   catch-up, children age 7-18 years, 262
   children, age 0-6 years, 256
   children, age 7-18 years, 258
   storage and transport, 117t, 118
vs zoster (shingles) vaccine, 37-38
vs smallpox, 428, 430t-431t
waning immunity and, 460
Varicella-zoster immune globulin. See VariZIG.
Varicella-zoster virus (VZV), 459. See also Varicella.
reactivation of latent, 22, 459, 460.
   See also Zoster (herpes zoster; shingles).
Variola, 427. See also Smallpox.
last remaining stocks of, 48-49
major vs. minor, 427-428
Varivax (varicella vaccine), 62t, 462-468, 463t.
   See also Varicella, vaccines.
VariZIG, 168, 467-468. See also Varicella.
interval for live vaccines and, 155t
investigational new-drug protocol, obtaining under, 368
pregnancy and, 185
Veterinarians, 202t
VFC. See Vaccines for Children (VFC) Program.
VICP. See Vaccine Injury Compensation Program.
Viral interference, 486
Vivotif (Ty21a, live-attenuated typhoid vaccine), 453-456,
454t-455t
Voices for Vaccines, 501
VRBPAC (Vaccines and Related Biological Products Advisory
Committee), 60-61, 65
Vulvar intraepithelial neoplasia (VIN), 332
Waning immunity, 29, 190, 223, 287, 460
Warnings, 106, 162. See also Contraindications and
precautions.
Whole agent vaccines, 14t, 20
Whooping cough, 284. See also Pertussis.
Woolsorter’s disease, 275
World Health Organization (WHO), 55, 499
Wound management, tetanus prophylaxis for, 298t-299t
X-linked agammaglobulinemia, 166
Yellow fever, 471-476, 511t
certificates of vaccination, 196, 475-476
clinical features, 471
epidemiology and transmission, 471-472
immunization program, 472
pathogen, 471
vaccine for, 472, 473t
adverse events, serious, 474
contraindications/precautions, 169, 474-475
efficacy/immunogenicity, 23, 473-474
recommendations, 475-476
travel, 196, 198t-200t, 475-476
safety, 474-475
storage, 117t
YF-Vax (yellow fever vaccine), 473t. See also Yellow fever.
Youth Risk Behavior Study, 334

Zostavax (ZOS, zoster vaccine), 63t, 480-483, 481t
Zoster (herpes zoster; shingles), 37, 459, 460, 477-484, 511t.
See also Varicella.
clinical features, 477-478
epidemiology and transmission, 478-479
immunization program, 479-480
incidence, 478-479
pathogen, 459, 477
postherpetic neuralgia (PHN) and, 477, 478
vaccine for, 480, 481t
administration errors and remedies, 159t
contraindications/precautions, 22, 482
cost-benefit of vaccination, 223, 480
efficacy/immunogenicity, 480-481
minimum ages and intervals, 143, 148t
recommendations, 63t, 482-483
safety, 482
schedule
adults, by age, 264
adults, by medical condition/indication, 267
storage, 117t
vs varicella vaccine, 37-38
zoster sine herpete, 478